Literature DB >> 9129241

Autocrine growth inhibition of IL-1 beta-treated cultured human aortic smooth muscle cells: possible role of nitric oxide.

S Makita1, M Nakamura, H Yoshida, K Hiramori.   

Abstract

This study was designed to investigate whether interleukin (IL)-1 beta would stimulate nitric oxide (NO) production in cultured aortic vascular smooth muscle cells (VSMCs), and to determine the basic effect of the liberated NO on VSMC proliferation. NO production was estimated from nitrite concentration of culture medium in multi-well plates, determined by the Griess method. VSMCs were IL-1 beta-pretreated in insert cups, and co-cultured with untreated VSMC in the wells. 3H-thymidine (3H-Tdr) incorporation into the VSMC in wells was evaluated for VSMC proliferative activity. IL-1 beta stimulated NO production in VSMCs in a concentration-dependent manner. This effect was further enhanced by the addition of a membrane-permeable cyclic adenosine monophosphate derivative, dibutyryl cyclic AMP (db-cAMP), and was significantly reduced by concomitant use of an NO synthase inhibitor, NG-nitro-L-arginine methyl ester (L-NAME). IL-1 beta-pretreated VSMCs significantly inhibited 3H-Tdr incorporation of the co-cultured VSMC. This inhibitory effect was significantly enhanced by the addition of db-cAMP, while this inhibition was significantly decreased by preincubation with L-NAME, and was abolished in the L-arginine-free medium. These results suggest that, in human VSMC, IL-1 beta stimulates NO production that is enhanced by intracellular cAMP accumulation, and that the liberated NO inhibits further VSMC proliferation in an autocrine fashion.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9129241     DOI: 10.1007/bf01746201

Source DB:  PubMed          Journal:  Heart Vessels        ISSN: 0910-8327            Impact factor:   2.037


  26 in total

1.  The role of nitric oxide in endothelial cell damage and its inhibition by glucocorticoids.

Authors:  R M Palmer; L Bridge; N A Foxwell; S Moncada
Journal:  Br J Pharmacol       Date:  1992-01       Impact factor: 8.739

2.  Nitric oxide from vascular smooth muscle cells: regulation of platelet reactivity and smooth muscle cell guanylate cyclase.

Authors:  V Mollace; D Salvemini; E Anggard; J Vane
Journal:  Br J Pharmacol       Date:  1991-11       Impact factor: 8.739

Review 3.  Signal transduction mechanisms involving nitric oxide.

Authors:  L J Ignarro
Journal:  Biochem Pharmacol       Date:  1991-02-15       Impact factor: 5.858

4.  Nitric oxide-generating vasodilators and 8-bromo-cyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells.

Authors:  U C Garg; A Hassid
Journal:  J Clin Invest       Date:  1989-05       Impact factor: 14.808

5.  Cytokine-induced expression of an inducible type of nitric oxide synthase gene in cultured vascular smooth muscle cells.

Authors:  M Koide; Y Kawahara; T Tsuda; M Yokoyama
Journal:  FEBS Lett       Date:  1993-03-08       Impact factor: 4.124

6.  Tyrosine kinase inhibitors suppress endotoxin- and IL-1 beta-induced NO synthesis in aortic smooth muscle cells.

Authors:  N Marczin; A Papapetropoulos; J D Catravas
Journal:  Am J Physiol       Date:  1993-09

7.  Vascular endothelial cells synthesize nitric oxide from L-arginine.

Authors:  R M Palmer; D S Ashton; S Moncada
Journal:  Nature       Date:  1988-06-16       Impact factor: 49.962

8.  Interferon-gamma and tumor necrosis factor synergize to induce nitric oxide production and inhibit mitochondrial respiration in vascular smooth muscle cells.

Authors:  Y Geng; G K Hansson; E Holme
Journal:  Circ Res       Date:  1992-11       Impact factor: 17.367

9.  Inhibition of cytokine-induced nitric oxide production by transforming growth factor-beta 1 in human smooth muscle cells.

Authors:  D C Junquero; T Scott-Burden; V B Schini; P M Vanhoutte
Journal:  J Physiol       Date:  1992-08       Impact factor: 5.182

10.  Induction of nitric oxide synthase in cultured vascular smooth muscle cells: the role of cyclic AMP.

Authors:  K Hirokawa; K O'Shaughnessy; K Moore; P Ramrakha; M R Wilkins
Journal:  Br J Pharmacol       Date:  1994-06       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.